BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 30, 2021
View Archived Issues
Cybin reports preclinical data on deuteration modifications in psychedelic molecules
Read More
Wigen Biomedicine Technology presents new Aurora kinase inhibitors
Read More
Shenzhen Salubris Pharmaceuticals patents factor XIa inhibitors
Read More
Shanghai Yingli Pharmaceutical describes new GTPase KRAS inhibitors
Read More
Medshine Discovery identifies new ERK-2 inhibitors
Read More
Henan Zhiwei Biomedicine, Henan Normal University patent Bruton tyrosine kinase inhibitors
Read More
Antitumor activity of novel prodrug TRN-000546
Read More
mGluR2 ago-PAM [18F]mG2P026 shows in vivo promise as a PET-imaging ligand
Read More
Loss-of-function mutations in IPO8 lead to syndromic thoracic aortic aneurysm
Read More
A dimeric LAIR-2 Fc fusion protein targets tumor ECM and promotes T-cell function by blocking LAIR-1
Read More
Encouraging phase II results seen with bomedemstat in essential thrombocythemia, myelofibrosis
Read More
Iovance provides clinical data for LN-145 in mNSCLC
Read More
Teneurin-4 identified as potential target and biomarker for triple negative breast cancer
Read More
First patient dosed in phase I/IIa trial of PRL-02 in metastatic prostate cancer
Read More
Positive phase Ib data reported for CVL-231 in patients with schizophrenia
Read More
Ori-CAR-001 CAR T-cell therapy targeting glypican-3 safe in phase I study
Read More
Initial phase I data for VBI-2902a, an enveloped virus-like particle COVID-19 vaccine candidate
Read More
FDA clears IND application for CLN-619 for the treatment of solid tumors
Read More
Elicio initiates phase I/II AMPLIFY-201 study of ELI-002 in KRAS-driven cancers
Read More
Trial finds rice-based oral cholera vaccine safe, effective
Read More
Dosing begins in phase Ib/II study of TTI-621 with doxorubicin in leiomyosarcoma
Read More
Novel miRNAs found with prognostic value in heart failure
Read More
Altimmune discontinues AdCOVID development, updates T-COVID progress
Read More
Endpoints not met in phase II trial of ANG-3777 in COVID-19-associated pneumonia
Read More
FDA approves IND for phase I/II trial of ExoFlo for mild to moderate COVID-19
Read More
HZN-7734 enters phase II study for SLE
Read More
Alnylam initiates phase II study of zilebesiran for mild to moderate hypertension
Read More
Saniona begins phase I trial of SAN-711 for neuropathic disorders
Read More